This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Standard chemotherapy (doxorubicin, cyclophosphamide plus paclitaxel) was compared with standard chemotherapy followed by weekly trastuzumab (2 mg/kg per week). A hypothetical cohort of women had a median age of 50 years, HER2-positive early breast cancer and weighed 60 kg.
Location/setting
Italy/USA. Outpatient care.
Methods

Analytical approach:
A Markov model was used to synthesise data from a combined report of the National Surgical Adjuvant Breast and Bowel Project-B31 and the North Central Cancer Treatment Group N9831 randomised clinical trials (Romond et al. 2005 , see 'Other Publications of Related Interest' below for bibliographic details). Full details are not reported in this paper. These trials were selected for having the longest follow-up periods of existing trials evaluating trastuzumab. The analysis was over a 15-year period and the authors stated the study perspective to be that of the Italian and US health care systems.
Effectiveness data:
The clinical estimates included the rate of relapse, disease-free time, metastatic disease, deaths and the adverse sideeffect of cardiac dysfunction. Evidence of the clinical estimates was abstracted from meta-analyses, randomised clinical trials and a longitudinal cohort study.
Monetary benefit and utility valuations:
Utility weights were assigned to the health states and derived from three published articles, of which two were of women with early breast cancer. The utility methods were not reported.
Measure of benefit:
The two measures of benefit used were the life-years gained and quality-adjusted life-years (QALYs). Discounting was applied at a rate of 3%.
